Abizer Gaslightwala

Chief Executive Officer at AKARI THERAPEUTICS, PLC

Net worth: 6 149 $ as of 31/05/2025

52 year

54 connections

Health Technology

Consumer Services

Finance

Profile

Mr. Abizer Gaslightwala is a President, Chief Executive Officer & Director at Akari Therapeutics Plc and a Senior Vice President at Jazz Pharmaceuticals Plc.
He is on the Board of Directors at Akari Therapeutics Plc.
He received his undergraduate degree from Cornell University, a graduate degree from Massachusetts Institute of Technology and an MBA from MIT Sloan School of Management.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
AKARI THERAPEUTICS PLC 0.44%	24/06/2026	614,856,000 ( 0.44% )	6 149 $	31/05/2025

Abizer Gaslightwala active positions

Companies	Position	Start
AKARI THERAPEUTICS, PLC	Chief Executive Officer	21/04/2025
JAZZ PHARMACEUTICALS PLC	Corporate Officer/Principal	01/10/2020

All active positions of Abizer Gaslightwala

Training of Abizer Gaslightwala

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Abizer Gaslightwala's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Massachusetts Institute of Technology Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University	Finance
Cornell University Cornell University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Jazz Pharmaceuticals Plc Jazz Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of pharmaceutical products to treat neurological disorders	Health Technology
MIT Sloan School of Management MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Akari Therapeutics Plc Akari Therapeutics Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapies for autoimmune and inflammatory diseases	Health Technology